Mark Levick
Direttore/Membro del Consiglio presso InterAx Biotech AG
Profilo
Mark Levick is currently the Director at InterAx Biotech AG since 2023.
Prior to this, he was the Chief Executive Officer at Alvotech hf and Alvotech from 2019 to 2023.
He also served as the Global Head at Novartis AG and Global Head-Development at Sandoz Biopharmaceuticals from 2016 to 2019.
Dr. Levick holds a doctorate degree from the University of Cambridge and an undergraduate degree from The University of Newcastle.
Posizioni attive di Mark Levick
| Società | Posizione | Inizio |
|---|---|---|
InterAx Biotech AG
 InterAx Biotech AG Miscellaneous Commercial ServicesCommercial Services InterAx Biotech AG engages in assisting drug candidate design and selection. It focuses on the development of its systems biology platform. The company was founded by Martin Ostermaier, Aurelien Rizk, and Luca Zenone and is headquartered in Villigen, Switzerland. | Direttore/Membro del Consiglio | 03/10/2023 |
Precedenti posizioni note di Mark Levick
| Società | Posizione | Fine |
|---|---|---|
| ALVOTECH | Amministratore Delegato | 01/01/2023 |
| Sandoz Biopharmaceuticals | Corporate Officer/Principal | 01/01/2019 |
| NOVARTIS AG | Corporate Officer/Principal | 01/07/2016 |
Alvotech hf
 Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | Amministratore Delegato | - |
Formazione di Mark Levick
| University of Cambridge | Doctorate Degree |
| The University of Newcastle | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| NOVARTIS AG | Health Technology |
| ALVOTECH | Health Technology |
| Aziende private | 3 |
|---|---|
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | Health Technology |
InterAx Biotech AG
InterAx Biotech AG Miscellaneous Commercial ServicesCommercial Services InterAx Biotech AG engages in assisting drug candidate design and selection. It focuses on the development of its systems biology platform. The company was founded by Martin Ostermaier, Aurelien Rizk, and Luca Zenone and is headquartered in Villigen, Switzerland. | Commercial Services |
| Sandoz Biopharmaceuticals |
- Borsa valori
- Insiders
- Mark Levick
